Table 2.
Treatment characteristics
| n (%) | |
|---|---|
| Neoadjuvant chemotherapy | 33 (49) |
| Anthracycline-based | 21 (57) |
| Taxane-based (no anthracyclines) | 9 (24) |
| Other | 3 (8) |
| Adjuvant Chemotherapy | 37 (55) |
| Anthracycline regimen | 24 (65) |
| Taxane-based | 12 (33) |
| No chemotherapy received | 5 (7) |
| Both neoadjuvant and adjuvant chemotherapy | 8 (12) |
| Adjuvant tamoxifen (ER/PR+) | 22/53 (42) |
| Adjuvant AI (ER/PR+) | 23/52 (43) |
| Both | 1 (1) |
| No hormone therapy (ER/PR+) | 8/53 (15) |
| Pretherapy nodal bx (neoadjuvant) | |
| Negative | 2 |
| Positive | 19 |
| Convert to pCR nodes from + nodes | 5/27 (19) |
| pCR, breast only | 10/33 (30) |
| pCR, both | 5/33 (15) |
| No nodal evaluation (T3N0) | 1 (1) |
| Sentinel node only | 10 (15) |
| Axillary dissection | 56 (84) |
| Range of nodes dissected | 3-29 |
| Median no. of nodes | 12.5 |
| Range positive | 0-16 |
| Median positive | 2 |
| Breast reconstruction | |
| Yes | 41 (59) |
| No | 28 (41) |
Abbreviations: AI = aromatase inhibitor; ER = estrogen receptor; pCR = pathologic complete response; PR = progesterone receptor.